Open AccessGut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights
Author(s) -
Tong Guo,
Li Chen
Publication year - 2022
Publication title -
european journal of inflammation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.219
H-Index - 20
eISSN - 2058-7392
pISSN - 1721-727X
DOI - 10.1177/1721727x221083763
Subject(s) - parkinson's disease , disease , gut flora , fecal bacteriotherapy , pathogenesis , dopaminergic , inflammation , medicine , population , immunology , bioinformatics , antibiotics , biology , dopamine , environmental health , clostridium difficile , microbiology and biotechnology
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by dopaminergic neuronal loss and α-synuclein (α-syn) aggregation. With the acceleration of population aging process, the incidence of PD is expected to increase, putting a heavy burden on the whole society. Recent studies have found the alterations of gut microbiota (GM) in PD patients and the clinical relevance of these changes, indicating the underlying relationship between GM and PD. Additionally, elevated inflammatory responses originating from the gut play a crucial role in the initiation and progression of PD, which is closely associated with GM. In this review, we will summarize recent studies on the correlation between GM and PD, and discuss the possible pathogenesis of PD mediated by GM and subsequent inflammatory cascades. We will also focus on the promising GM-based therapeutic strategies of PD, including antibiotics, probiotics and/or prebiotics, fecal microbiota transplantation, and dietary interventions, aiming to provide some new therapeutic insights for PD.